Supplementary Table 3.
Analysis of correlation between PMS2 expression, clinico-pathological features and markers in 245 invasive breast carcinomas
| N | PMS2 negative (n=2) | PMS2 positive (n=169) | PMS2 inconclusive (n=1) | p value* | |
|---|---|---|---|---|---|
| Tumour size | 170 | 0.853 | |||
| T1 | 1 | 82 | 0 | ||
| T2 | 1 | 75 | 1 | ||
| T3 | 0 | 10 | 0 | ||
| Histological grade | 168 | 0.444 | |||
| I | 1 | 19 | 0 | ||
| II | 0 | 47 | 0 | ||
| III | 1 | 99 | 1 | ||
| Lympho-vascular invasion | 170 | 0.676 | |||
| present | 1 | 115 | 1 | ||
| absent | 1 | 52 | 0 | ||
| Lymph node metastasis | 166 | 0.042 | |||
| present | 0 | 112 | 0 | ||
| absent | 2 | 51 | 1 | ||
| ER | 172 | 0.352 | |||
| positive | 1 | 144 | 1 | ||
| negative | 1 | 25 | 0 | ||
| PR | 172 | 0.592 | |||
| positive | 2 | 125 | 1 | ||
| negative | 0 | 44 | 0 | ||
| HER2 | 172 | 0.771 | |||
| positive | 0 | 25 | 0 | ||
| negative | 2 | 144 | 1 | ||
| Ki67 | 160 | 0.771 | |||
| low (<10%) | 1 | 72 | 0 | ||
| intermediate | 1 | 63 | 1 | ||
| high (>30%) | 0 | 22 | 0 | ||
| Topoisomerase IIα | 158 | 0.657 | |||
| positive | 1 | 85 | 1 | ||
| negative | 1 | 70 | 0 | ||
| Cyclin D1 | 163 | 0.003 | |||
| low (Allred score 0-3) | 2 | 17 | 0 | ||
| intermediate (Allred score 4-5) | 0 | 34 | 0 | ||
| high (Allred score 6-8) | 0 | 109 | 1 | ||
| Bcl2 | 139 | 0.615 | |||
| positive | 1 | 92 | 1 | ||
| negative | 0 | 45 | 0 | ||
| FOXA1 | 140 | 0.713 | |||
| positive | 1 | 103 | 1 | ||
| negative | 0 | 35 | 0 | ||
| P53 | 160 | 0.188 | |||
| positive | 0 | 44 | 1 | ||
| negative | 2 | 113 | 0 | ||
| Cytokeratin 5/6 | 164 | 0.148 | |||
| positive | 1 | 15 | 0 | ||
| negative | 1 | 146 | 1 | ||
| Cytokeratin 14 | 170 | 0.093 | |||
| positive | 1 | 13 | 0 | ||
| negative | 1 | 154 | 1 | ||
| Cytokeratin 17 | 168 | 0.208 | |||
| positive | 1 | 18 | 0 | ||
| negative | 1 | 147 | 1 | ||
| Basal cytokeratins | 170 | 0.294 | |||
| positive | 1 | 22 | 0 | ||
| negative | 1 | 145 | 1 | ||
| EGFR | 172 | 0.110 | |||
| positive | 1 | 14 | 0 | ||
| negative | 1 | 155 | 1 | ||
| Caveolin 1 | 172 | 0.110 | |||
| positive | 1 | 14 | 0 | ||
| negative | 1 | 155 | 1 | ||
| Caveolin 2 | 159 | 0.052 | |||
| positive | 1 | 10 | 0 | ||
| negative | 1 | 146 | 1 | ||
| Nestin | 140 | 0.885 | |||
| positive | 0 | 15 | 0 | ||
| negative | 1 | 123 | 1 | ||
| Any basal marker | 170 | 0.358 | |||
| positive | 1 | 25 | 0 | ||
| negative | 1 | 142 | 1 | ||
| Molecular phenotype** | 169 | 0.512 | |||
| luminal | 1 | 123 | 1 | ||
| HER2+ | 0 | 24 | 0 | ||
| basal-like | 1 | 19 | 0 | ||
| E-cadherin | 159 | 0.781 | |||
| normal | 2 | 98 | 1 | ||
| reduced | 0 | 10 | 0 | ||
| negative | 0 | 48 | 0 | ||
| HER2 CISH | 162 | 0.777 | |||
| amplified | 0 | 23 | 0 | ||
| not amplified | 2 | 136 | 1 | ||
| TOP2A CISH | 163 | 0.857 | |||
| amplified | 0 | 15 | 0 | ||
| not amplified | 2 | 145 | 1 | ||
| CCND1 CISH | 169 | 0.030 | |||
| amplified | 0 | 21 | 1 | ||
| not amplified | 2 | 145 | 0 |
*
Chi-squared test
**
according to criteria by Nielsen et al [53].
CCND1: cyclin D1 gene; CISH: chromogenic in situ hybridisation; PMS2: postmeiotic segregation increased 2; TOP2A: topoisomerase II. gene.